Quick Summary:
In the ever-evolving healthcare industry, keeping abreast of key market movements is imperative to your strategic decisions. Our market report on the thriving global Myasthenia Gravis Drugs market provides the key insights you need to stay ahead in this evolving landscape.
This in-depth and comprehensive analysis forecasts a burgeoning market set to escalate from the current US$1.8 billion to a promising US$3.1 billion by 2030. This report offers you insights on significant segments, with Drug Treatment predicted to reach US$1.8 billion. The report also covers regional performances; highlighting opportunities in key economies such as the U.S and China, with the latter projected to grow at a 6.2% CAGR.
Stay informed with our competitive analysis involving big industry names like Alexion Pharmaceuticals and GlaxoSmithKline PLC, alongside a host of other features that this report offers. Recognize the opportunities in this growing market and inform your strategies with our vital report.
Global Myasthenia Gravis Drugs Market to Reach $3.1 Billion by 2030
The global market for Myasthenia Gravis Drugs estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2022-2030. Drug Treatment, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Rapid Immunotherapies segment is readjusted to a revised 5.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $553.5 Million, While China is Forecast to Grow at 6.2% CAGR
The Myasthenia Gravis Drugs market in the U.S. is estimated at US$553.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$530.1 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 5.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.Select Competitors (Total 18 Featured) -
- Alexion Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
- Catalyst Pharmaceuticals, Inc.
- CSL Limited
- Curavac Inc.
- Cytokinetics, Inc.
- F. Hoffmann-La Roche AG
- Flamel Technologies S.A.
- Galenica Ltd.
- GlaxoSmithKline PLC
- Grifols SA
- Lupin Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis International AG
- Pfizer, Inc.
- Shire PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Myasthenia Gravis Drugs?
What is the growth rate of the Global Market for Myasthenia Gravis Drugs?
What is the forecasted size of the Global Market for Myasthenia Gravis Drugs?
Who are the key companies in the Global Market for Myasthenia Gravis Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 3.1 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alexion Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
- Catalyst Pharmaceuticals, Inc.
- CSL Limited
- Curavac Inc.
- Cytokinetics, Inc.
- F. Hoffmann-La Roche AG
- Flamel Technologies S.A.
- Galenica Ltd.
- GlaxoSmithKline PLC
- Grifols SA
- Lupin Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis International AG
- Pfizer, Inc.
- Shire PLC
